181 related articles for article (PubMed ID: 31611394)
1. PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor.
Diehl KL; Ge EJ; Weinberg DN; Jani KS; Allis CD; Muir TW
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22152-22157. PubMed ID: 31611394
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
4. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
[TBL] [Abstract][Full Text] [Related]
5. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
[TBL] [Abstract][Full Text] [Related]
6. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
7. C10ORF12 modulates PRC2 histone methyltransferase activity and H3K27me3 levels.
Shi Y; Ma HL; Zhuang YW; Wang XX; Jiang Y; Xu HE
Acta Pharmacol Sin; 2019 Nov; 40(11):1457-1465. PubMed ID: 31186533
[TBL] [Abstract][Full Text] [Related]
8. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.
Stafford JM; Lee CH; Voigt P; Descostes N; Saldaña-Meyer R; Yu JR; Leroy G; Oksuz O; Chapman JR; Suarez F; Modrek AS; Bayin NS; Placantonakis DG; Karajannis MA; Snuderl M; Ueberheide B; Reinberg D
Sci Adv; 2018 Oct; 4(10):eaau5935. PubMed ID: 30402543
[TBL] [Abstract][Full Text] [Related]
9. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
Ren Z; Ahn JH; Liu H; Tsai YH; Bhanu NV; Koss B; Allison DF; Ma A; Storey AJ; Wang P; Mackintosh SG; Edmondson RD; Groen RWJ; Martens AC; Garcia BA; Tackett AJ; Jin J; Cai L; Zheng D; Wang GG
Blood; 2019 Oct; 134(14):1176-1189. PubMed ID: 31383640
[TBL] [Abstract][Full Text] [Related]
10. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
11. Strategy for "detoxification" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.
Brown ZZ; Müller MM; Jain SU; Allis CD; Lewis PW; Muir TW
J Am Chem Soc; 2014 Oct; 136(39):13498-501. PubMed ID: 25180930
[TBL] [Abstract][Full Text] [Related]
12. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
13. Histone methylation by PRC2 is inhibited by active chromatin marks.
Schmitges FW; Prusty AB; Faty M; Stützer A; Lingaraju GM; Aiwazian J; Sack R; Hess D; Li L; Zhou S; Bunker RD; Wirth U; Bouwmeester T; Bauer A; Ly-Hartig N; Zhao K; Chan H; Gu J; Gut H; Fischle W; Müller J; Thomä NH
Mol Cell; 2011 May; 42(3):330-41. PubMed ID: 21549310
[TBL] [Abstract][Full Text] [Related]
14. Single-molecule and in silico dissection of the interaction between Polycomb repressive complex 2 and chromatin.
Leicher R; Ge EJ; Lin X; Reynolds MJ; Xie W; Walz T; Zhang B; Muir TW; Liu S
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30465-30475. PubMed ID: 33208532
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA.
Wang X; Paucek RD; Gooding AR; Brown ZZ; Ge EJ; Muir TW; Cech TR
Nat Struct Mol Biol; 2017 Dec; 24(12):1028-1038. PubMed ID: 29058709
[TBL] [Abstract][Full Text] [Related]
16. A Modular Ligation Strategy for Asymmetric Bivalent Nucleosomes Trimethylated at K36 and K27.
Guidotti N; Lechner CC; Bachmann AL; Fierz B
Chembiochem; 2019 May; 20(9):1124-1128. PubMed ID: 30615245
[TBL] [Abstract][Full Text] [Related]
17. Recent Structural Insights into Polycomb Repressive Complex 2 Regulation and Substrate Binding.
Kasinath V; Poepsel S; Nogales E
Biochemistry; 2019 Feb; 58(5):346-354. PubMed ID: 30451485
[TBL] [Abstract][Full Text] [Related]
18. Nucleation and Propagation of Heterochromatin by the Histone Methyltransferase PRC2: Geometric Constraints and Impact of the Regulatory Subunit JARID2.
Ge EJ; Jani KS; Diehl KL; Müller MM; Muir TW
J Am Chem Soc; 2019 Sep; 141(38):15029-15039. PubMed ID: 31479253
[TBL] [Abstract][Full Text] [Related]
19. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling.
Herz HM; Morgan M; Gao X; Jackson J; Rickels R; Swanson SK; Florens L; Washburn MP; Eissenberg JC; Shilatifard A
Science; 2014 Aug; 345(6200):1065-70. PubMed ID: 25170156
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
